

***Mesoblast Limited***  
***ABN 68 109 431 870***  
**and Controlled Entities (Mesoblast Group)**

**HALF-YEAR INFORMATION**  
**FOR THE SIX MONTHS ENDED 31 DECEMBER 2014**  
**PROVIDED TO THE ASX UNDER LISTING RULE 4.2A**

**This half-year financial report is to be read in conjunction with the financial report for the period ended 30 June 2014.**

# Appendix 4D

## Half-Year Report for the six months to 31 December 2014

Name of entity

MESOBLAST LIMITED ABN 68 109 431 870
---

### 1. Reporting period

Report for the half-year ended	31 December 2014
Previous corresponding period is the financial year ended and half-year ended	30 June 2014 31 December 2013

### 2. Results for announcement to the market

	Up/down	% change		Amount reported for the half-year ended 31 December 2014 \$000
Revenues from ordinary activities ( <i>item 2.1</i> )	Up	24%	to	25,850
Loss from ordinary activities after tax attributable to members ( <i>item 2.2</i> )	Up*	65%	to	50,818
Net loss for the period attributable to members ( <i>item 2.3</i> )	Up*	65%	to	50,818
<i>*increase in loss</i>				
There are no dividends being proposed or declared for the period ( <i>item 2.4</i> )				
Date for determining entitlements to the dividends: N/A ( <i>item 2.5</i> )				
Brief explanation of any of the figures reported above necessary to enable the figures to be understood ( <i>item 2.6</i> ):				
Please refer to the Directors' Report section of the Half-Year Report (31 December 2014) and the accompanying press release.				

**3. Net tangible assets per security (item 3)**

	<b>31 December 2014</b>	<b>31 December 2013</b>
Net tangible (liability) / asset backing per ordinary security	(7.88) cents	25.02 cents

A large proportion of the company's assets are intangible in nature, consisting of intellectual property and goodwill relating to the acquisition of Mesoblast, Inc and Culture-expanded Mesenchymal Stem Cells (ceMSCs) technology. These assets are excluded from the calculation of net tangible assets per security. A deferred tax liability of \$182,134k has also been excluded from the calculation to the extent it relates to future tax obligations as a result of the intellectual property assets deriving revenue at some point in the future. This deferred tax liability has arisen as a direct result of the intellectual property being acquired.

**4. Half-Year Financial Statements and Directors' Report**

The financial information provided in the Appendix 4D should be read in conjunction with the half-year financial statements and Directors' report (attached), which has been prepared in accordance with Australian Accounting Standards.

**5. Independent review of the financial report (item 9)**

The financial report has been independently reviewed. The financial report is not subject to a qualified independent review statement. The independent audit review report is attached to the financial statements.